Nabi Biopharmaceuticals in $100 Million Convertible Notes Offering

April 19, 2005

Cleary Gottlieb represented the initial purchasers in Nabi Biopharmaceuticals, Inc.’s Rule 144A offering of 2.875% convertible senior notes due 2025.  Lehman Brothers served as representative to the initial purchasers in the transaction, which is valued at $100 million.

Nabi, a biopharmaceutical company, is the developer of StaphVAX, the first vaccine designed to protect people from staph infections, commonly seen in hospital patients.